WO1998023761A1 - HUMANIZED ANTI-CD11a ANTIBODIES - Google Patents

HUMANIZED ANTI-CD11a ANTIBODIES Download PDF

Info

Publication number
WO1998023761A1
WO1998023761A1 PCT/US1997/019041 US9719041W WO9823761A1 WO 1998023761 A1 WO1998023761 A1 WO 1998023761A1 US 9719041 W US9719041 W US 9719041W WO 9823761 A1 WO9823761 A1 WO 9823761A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cdl
seq
human
cells
Prior art date
Application number
PCT/US1997/019041
Other languages
English (en)
French (fr)
Inventor
Paula M. Jardieu
Leonard G. Presta
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT97912841T priority Critical patent/ATE267257T1/de
Priority to JP52464598A priority patent/JP3778945B2/ja
Priority to DE200412000047 priority patent/DE122004000047I1/de
Priority to IL13014397A priority patent/IL130143A0/xx
Priority to DE69729209T priority patent/DE69729209T2/de
Priority to CA2272842A priority patent/CA2272842C/en
Priority to AU49929/97A priority patent/AU731817C/en
Priority to EP97912841A priority patent/EP0941344B1/en
Priority to DE1997629209 priority patent/DE122004000047I2/de
Priority to KR10-1999-7004671A priority patent/KR100532178B1/ko
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of WO1998023761A1 publication Critical patent/WO1998023761A1/en
Priority to IL130143A priority patent/IL130143A/en
Priority to LU91122C priority patent/LU91122I2/fr
Priority to NL300163C priority patent/NL300163I2/nl
Priority to FR04C0028C priority patent/FR04C0028I2/fr
Priority to IL175583A priority patent/IL175583A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Definitions

  • This invention relates generally to humanized anti-CDl la antibodies. Description of Related Art
  • Lymphocyte function-associated antigen 1 (LFA-1; CDl la/CD 18) is involved in leukocyte adhesion during cellular interactions essential for immunologic responses and inflammation (Larson et al, Immunol. Rev. 114:181-217 (1990)).
  • LFA-1 is a member of the ⁇ 2 integrin family and consists of a unique ⁇ subunit, CDl la, and a ⁇ subunit, CD18, common to other ⁇ 2 integrin receptors Mac-1 and pl50,95.
  • the ligands of LFA-1 include intercellular adhesion molecule- 1, ICAM-1, expressed on leukocytes, endothelium, and dermal fibroblasts (Dustin et al, J. Immunol.
  • ICAM-2 expressed on resting endothelium and lymphocytes (de Fougerolles et al, J. Exp. Med. 174:253-267 (1991)), and ICAM-3 expressed on monocytes and resting lymphocytes (de Fougerolles et al, J. Exp. Med. 179:619-629 (1994)).
  • T cell-dependent immune functions Monoclonal antibodies (MAbs) against LFA-1 and the ICAMs have been shown, in vitro, to inhibit several T cell-dependent immune functions including T cell activation (Kuypers et al, Res. Immunol. 140:461(1989)), T cell-dependent B cell proliferation (Fischer et al, J. Immunol. 136:3198-3203 (1986)), target cell lysis (Krensky et al, J. Immunol. 131 :611-616 (1983)), and adhesion of T cells to vascular endothelium (Lo et al, J. Immunol. 143:3325-3329 (1989)).
  • OKT3 therapy is effective but has several undesirable side effects; its use results in the release of numerous cytokines including tumor necrosis factor- ⁇ , interferon- ⁇ , interleukin-2, and interleukin-6, resulting in fever, chills and gastrointestinal distress (for a review see Parlevliet ef ⁇ /., Transplant Intl. 5:234-246 (1992); Dantal ef ⁇ z/., Curr. Opin. Immunol. 3:740- 747 (1991)). Cyclosporin A is effective but also has serious side effects (for a review see Barry, Drugs, 44:554-566 (1992)). SUMMARY OF THE INVENTION
  • the instant invention provides humanized anti-CDl la antibodies.
  • Preferred antibodies bind to the I-domain of human CDl la (e.g. to "epitope MHM24" as herein defined) and/or bind CDl la with an affinity of about 1 x 10 " M or stronger.
  • the antibody has an IC50 (nM) value of no more than about InM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1.
  • Preferred humanized antibodies are those which have an IC50 (nM) value of no more than about InM in the mixed lymphocyte response (MLR) assay.
  • MLR mixed lymphocyte response
  • the humanized anti-CDl la antibody may have a heavy chain variable region comprising the amino acid sequence of CDR1 (GYSFTGHWMN; SEQ ID NO: 10) and/or CDR2 (MIHPSDSETRYNQKFKD; SEQ ID NO: l 1) and or CDR3 (GIYFYGTTYFDY; SEQ ID NO: 12) of humanized antibody MHM24 F(ab)-8 in Fig.
  • a light chain variable region comprising the amino acid sequence of CDR1 (RASKTISKYLA; SEQ ID NO: 13) and/or CDR2 (SGSTLQS; SEQ ID NO: 14) and/or CDR3 (QQHNEYPLT; SEQ ID NO: 15) of humanized antibody MHM24 F(ab)-8 in Fig. 1.
  • the antibody comprises an amino acid sequence variant of one or more of the CDRs of humanized MHM24 antibody F(ab)-8, which variant comprises one or more amino acid insertion(s) within or adjacent to a CDR residue and/or deletion(s) within or adjacent to a CDR residue and/or substitution(s) of CDR residue(s) (with substitution(s) being the preferred type of amino acid alteration for generating such variants).
  • Such variants will normally having a binding affinity for human CDl la which is no more than about 1 x 10 " M.
  • the humanized antibody includes a light chain variable region comprising the amino acid sequence of SEQ ID NO:2 and/or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5 of humanized antibody MHM24 F(ab)-8 in Fig. 1 and/or amino acid sequence variants thereof.
  • a light chain variable region comprising the amino acid sequence of SEQ ID NO:2
  • a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5 of humanized antibody MHM24 F(ab)-8 in Fig. 1 and/or amino acid sequence variants thereof.
  • the antibody which binds rhesus CDl la may, for example, comprise the the CDR2 amino acid sequence in SEQ ID NO:23.
  • the other CDRs may be the same as those for humanized MHM24 antibody F(ab)-8.
  • the antibody may comprise the amino acid sequence of the "rhesusized" heavy chain in SEQ ID NO:24, optionally combined with a light chain comprising the amino acid sequence in SEQ ID NO:2.
  • the anti-CDl la antibody may be a full length antibody (e.g. having a human immunoglobulin constant region) or an antibody fragment (e.g. a F(ab')2)-
  • the antibody may be labeled with a detectable label, immobilized on a solid phase and/or conjugated with a heterologous compound (such as a cytotoxic agent).
  • the invention provides a method for determining the presence of CDl la protein comprising exposing a sample suspected of containing the CDl la protein to the anti-CDl la antibody and determining binding of the antibody to the sample.
  • the invention provides a kit comprising the antibody and instructions for using the antibody to detect the CD 11 a protein.
  • the invention further provides: isolated nucleic acid encoding the antibody; a vector comprising that nucleic acid, optionally operably linked to control sequences recognized by a host cell transformed with the vector; a host cell comprising that vector; a process for producing the antibody comprising culturing the host cell so that the nucleic acid is expressed and, optionally, recovering the antibody from the host cell culture (e.g. from the host cell culture medium).
  • the invention also provides a composition comprising the humanized anti- CD 1 la antibody and a pharmaceutically acceptable carrier or diluent. This composition for therapeutic use is sterile and may be lyophilized.
  • the invention further provides a method for treating a mammal suffering from a LFA-1 mediated disorder, comprising administering a pharmaceutically effective amount of the humanized anti-CD 11 a antibody to the mammal.
  • other immunosuppressive agents or adhesion molecule antagonists e.g. another LFA-1 antagonist or a VLA-4 antagonist
  • Figure 1A shows the amino acid sequences of murine MHM24 light chain (SEQ ID NO: 1), humanized MHM24 F(ab)-8 light chain (SEQ ID NO:2), human consensus sequences of light chain subgroup ⁇ l (hum ⁇ l) (SEQ ID NO:3).
  • Figure 1 B shows the amino acid sequences of murine MHM24 heavy chain (SEQ ID NO:4), humanized MHM24 F(ab)-8 heavy chain(SEQ ID NO:5), human consensus sequences of heavy chain subgroup III (humlll) (SEQ ID NO:6) and "rhesusized” antibody mutant heavy chain of the Example (SEQ ID NO:24).
  • Figs. lA and IB hypervariable regions based on sequence hypervariability (Kabat ef ⁇ /., Sequences of Proteins of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD.
  • Figures 4A-4C show inhibition of binding of rhesus lymphocytes to normal human keratinocytes (Fig. 4 A), rhesus lymphocytes to recombinant human ICAM-1 coated on plates (Fig.4B), and rhesus/human CDl la chimera-transfected 293 cells to normal human keratinocytes (Fig. 4C).
  • Inhibition by rhesus-binding MHM24 (RhlgGl) filled squares
  • anti-CD 18 MHM23 filled circles
  • a human IgGl isotype control (+) Figs. 4A and 4C
  • a murine IgGl isotype control (+) Fig. 4B.
  • Percent binding measured by fluorescence of labeled lymphocytes (Figs. 4A and B) or labeled 293 cells (Fig. 4C).
  • FIG. 5 shows human mixed lymphocyte response assy (MLR) is blocked by murine MHM24 (filled circles), humanized MHM24 (HulgG 1) (filled squares), and a humanized isotype IgGl control (filled diamond).
  • Percent stimulation index (%SI) is the ratio of the response at a given MAb concentration to the maximal response with no MAb present. Data is representative of multiple assays using at least two different stimulator/responder pairs. Detailed Description of the Preferred Embodiments I. Definitions
  • CDl la when used herein refers to the alpha subunit of LFA-1 from any mammal, but preferably from a human.
  • the CDl la may be isolated from a natural source of the molecule or may be produced by synthetic means (e.g., using recombinant DNA technology.)
  • the amino acid sequence for human CDl la is described in EP 362 526B1, for example.
  • I-domain of CDl la refers to the region of this molecule delineated in Champe et al, J. Bid. Chem.270: 1388-1394 (1995) and/or Qa etal. Proc. Natl. Acad. Sci. 92:10277-10281 (1995).
  • the amino acid sequences of human CDl la I-domain (SEQ ID NO:7) and rhesus CDl la I-domain (SEQ ID NO:8) are depicted in Fig. 2 herein.
  • epitopope MHM24 when used herein, unless indicated otherwise, refers to the region in the
  • This epitope comprises the amino acid sequence of SEQ ID NO:9 and, optionally, other amino acid residues of CDl la and/or CDl 8.
  • LFA-1 -mediated disorder refers to a pathological state caused by cell adherence interactions involving the LFA-1 receptor on lymphocytes.
  • T cell inflammatory responses such as inflammatory skin diseases including psoriasis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); adult respiratory distress syndrome; dermatitis; meningitis; encephalitis; uveitis; allergic conditions such as eczema and asthma; conditions involving infiltration of T cells and chronic inflammatory responses; skin hypersensitivity reactions (including poison ivy and poison oak); atherosclerosis; leukocyte adhesion deficiency; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetes mellitus, multiple sclerosis, Reynaud's syndrome, autoimmune thyroiditis, experimental autoimmune encephalomyelitis, Sjorgen's syndrome, juvenile onset diabetes, and immune responses associated with delayed
  • immunosuppressive agent refers to substances that act to suppress or mask the immune system of the host into which the graft is being transplanted. This would include substances that suppress cytokine production, downregulate or suppress self-antigen expression, or mask the MHC antigens. Examples of such agents include 2-amino-6-aryl-5-substituted pyrimidines (see U.S. Pat. No. 4,665,077), azathioprine (or cyclophosphamide, if there is an adverse reaction to azathioprine); bromocryptine; glutaraldehyde (which masks the MHC antigens, as described in U.S. Pat. No.
  • anti- idiotypic antibodies for MHC antigens and MHC fragments include cyclosporin A; steroids such as glucocorticosteroids, e.g., prednisone, methylprednisolone, and dexamethasone; cytokine or cytokine receptor antagonists including anti-interferon- ⁇ , - ⁇ , or - ⁇ antibodies; anti-tumor necrosis factor- ⁇ antibodies; anti- tumor necrosis factor- ⁇ antibodies; anti-interleukin-2 antibodies and anti-IL-2 receptor antibodies; anti-L3T4 antibodies; heterologous anti-lymphocyte globulin; pan-T antibodies, preferably anti-CD3 or anti-CD4/CD4a antibodies; soluble peptide containing a LFA-3 binding domain (WO 90/08187 published 7/26/90); streptokinase; TGF- ⁇ ; streptodomase; RNA or DNA from the host; FK506; RS-61443; dexamethasone
  • T-cell receptor fragments (Offher et al. Science 251 :430-432 (1991); WO 90/11294; and WO 91/01133); and T cell receptor antibodies (EP 340,109) such as T10B9.
  • T10B9 T cell receptor antibodies
  • adjunct immunosuppressive agent will depend on many factors, including the type of disorder being treated including the type of transplantation being performed, as well as the patient's history, but a general overall preference is that the agent be selected from cyclosporin A, a glucocorticosteroid (most preferably prednisone or methylprednisolone), OKT-3 monoclonal antibody, azathioprine, bromocryptine, heterologous anti-lymphocyte globulin, or a mixture thereof. "Treatment” refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
  • mammal for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human.
  • graft refers to biological material derived from a donor for transplantation into a recipient. Grafts include such diverse material as, for example, isolated cells such as islet cells and neural-derived cells (e.g. schwann cells), tissue such as the amniotic membrane of a newborn, bone marrow, hematopoietic precursor cells, and organs such as skin, heart, liver, spleen, pancreas, thyroid lobe, lung, kidney, tubular organs (e.g., intestine, blood vessels, or esophagus), etc. The tubular organs can be used to replace damaged portions of esophagus, blood vessels, or bile duct.
  • isolated cells such as islet cells and neural-derived cells (e.g. schwann cells)
  • tissue such as the amniotic membrane of a newborn, bone marrow, hematopoietic precursor cells
  • organs such as skin, heart, liver, spleen, pancreas, thyroid lobe
  • the skin grafts can be used not only for burns, but also as a dressing to damaged intestine or to close certain defects such as diaphragmatic hernia.
  • the graft is derived from any mammalian source, including human, whether from cadavers or living donors.
  • the graft is bone marrow or an organ such as heart and the donor of the graft and the host are matched for HLA class II antigens.
  • donor refers to the mammalian species, dead or alive, from which the graft is derived.
  • the donor is human.
  • Human donors are preferably volunteer blood-related donors that are normal on physical examination and of the same major ABO blood group, because crossing major blood group barriers possibly prejudices survival of the allograft. It is, however, possible to transplant, for example, a kidney of a type O donor into an A, B or AB recipient.
  • transplant refers to the insertion of a graft into a host, whether the transplantation is syngeneic (where the donor and recipient are genetically identical), allogeneic (where the donor and recipient are of different genetic origins but of the same species), or xenogeneic (where the donor and recipient are from different species).
  • the host is human and the graft is an isogrart, derived from a human of the same or different genetic origins.
  • the graft is derived from a species different from that into which it is transplanted, such as a baboon heart transplanted into a human recipient host, and including animals from phylogenically widely separated species, for example, a pig heart valve, or animal beta islet cells or neuronal cells transplanted into a human host.
  • a species different from that into which it is transplanted such as a baboon heart transplanted into a human recipient host, and including animals from phylogenically widely separated species, for example, a pig heart valve, or animal beta islet cells or neuronal cells transplanted into a human host.
  • "Increasing tolerance of a transplanted graft" by a host refers to prolonging the survival of a graft in a host in which it is transplanted, i.e., suppressing the immune system of the host so that it will better tolerate a foreign transplant.
  • “Intermittent” or “periodic” dosing is a dosing that is continuous for a certain period of time and is at regular intervals that are preferably separated by more than one day.
  • “Selective tolerance” of the disorder refers to a tolerance by the host's immune system for the specific agent causing the disorder, but retaining the ability of the host to reject a second allogeneic or xenogeneic graft. Preferably, the tolerance is such that the immune system is left otherwise intact.
  • LFA-1 antagonist refers to a molecule that acts as a competitive inhibitor of the LFA-1 interaction with ICAM-1.
  • examples of such molecules include antibodies directed against either CDl la (e.g., the humanized anti-CDl la antibodies described herein) or CD 18 or both, antibodies to ICAM-1, and other molecules such as peptides (e.g., peptidomimetic antagonists).
  • VLA-4 antagonist refers to a molecule that acts as a competitive inhibitor of the VLA-4 interaction with VCAM.
  • examples of such molecules include antibodies directed against either VLA-4 or VCAM and other molecules (e.g., peptidomimetic antagonists).
  • antibody is used in the broadest sense and specifically covers monoclonal antibodies
  • polyclonal antibodies including full length monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
  • multispecific antibodies e.g., bispecific antibodies
  • antibody fragments so long as they exhibit the desired biological activity.
  • Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable region thereof .
  • antibody fragments include Fab, Fab', F(ab')2 > and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al, Nature 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567).
  • the "monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al, Nature 352:624-628 (1991) and Marks et al, J. Mol. Biol. 222:581-597 (1991), for example.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison et al, Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)).
  • chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies
  • hypervariable region when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding.
  • the hypervariable region comprises amino acid residues from a "complementarity determining region" or "CDR" (i.e. residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (HI), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (i.e.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
  • the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • Single-chain Fv or “sFv” antibody fragments comprise the VJJ and V L domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the Vp j and V L domains which enables the sFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (VJJ) connected to a light chain variable domain (V j in the same polypeptide chain (V ⁇ - V j ).
  • VJJ heavy chain variable domain
  • V j light chain variable domain
  • V ⁇ - V j the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.
  • Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al, Proc. Natl Acad. Sci. USA 90:6444-6448 (1993).
  • linear antibodies when used throughout this application refers to the antibodies described in Zapata et al. Protein Eng. 8(10): 1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments ( p j -C jj l-Vp j -C jj l) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
  • an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • epitope tag polypeptide has enough residues to provide an epitope against which an antibody thereagainst can be made, yet is short enough such that it does not interfere with activity of the CDl la antibody.
  • the epitope tag preferably is sufficiently unique so that the antibody thereagainst does not substantially cross-react with other epitopes.
  • Suitable tag polypeptides generally have at least 6 amino acid residues and usually between about 8-50 amino acid residues (preferably between about 9-30 residues). Examples include the flu HA tag polypeptide and its antibody 12CA5 (Field etal.
  • the epitope tag is a "salvage receptor binding epitope".
  • the term "salvage receptor binding epitope” refers to an epitope of the Fc region of an IgG molecule (e.g., IgG j , IgG2, IgG , or I G ⁇ ) that is responsible for increasing the in vivo serum half-life of the IgG molecule.
  • cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
  • the term is intended to include radioactive isotopes (e.g., I , I , Y and Re ), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.
  • a “chemotherapeutic agent” is a chemical compound useful in the treatment of cancer.
  • chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Taxotere (docetaxel), Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan and other related nitrogen mustards.
  • prodrug refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic to tumor cells compared to the parent drug and is capable of being enzymatically activated or converted into the more active parent form. See, e.g., Wilman, "Prodrugs in Cancer Chemotherapy” Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Harbor (1986) and Stella et al, “Prodrugs: A Chemical Approach to Targeted Drug Delivery,” Directed Drug Delivery, Borchardt et al, (ed.), pp. 247-267, Humana Press (1985).
  • the prodrugs of this invention include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, ⁇ -lactam- containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted into the more active cytotoxic free drug.
  • cytotoxic drugs that can be derivatized into a prodrug form for use in this invention include, but are not limited to, those chemotherapeutic agents described above.
  • label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody.
  • the label may itself be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
  • solid phase is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g. controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
  • the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g. an affinity chromatography column).
  • This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.
  • a “liposome” is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as the anti-CDl la antibodies disclosed herein and, optionally, a chemotherapeutic agent) to a mammal.
  • the components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
  • An "isolated" nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the antibody nucleic acid.
  • An isolated nucleic acid molecule is other than in the form or setting in which it is found in nature.
  • Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells.
  • an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the antibody where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
  • control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
  • the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
  • Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • the expressions "cell,” “cell line,” and “cell culture” are used interchangeably and all such designations include progeny.
  • the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context. II. Modes for Carrying out the Invention
  • a method for humanizing a nonhuman CDl la antibody is described in the Example below. In order to humanize an anti-CDl la antibody, the nonhuman antibody starting material is prepared. Exemplary techniques for generating such antibodies will be described in the following sections. (/ ' ) Antigen preparation.
  • the CDl la antigen to be used for production of antibodies may be, e.g., a soluble form of the extracellular domain of CD 11 a or other fragment of CD 11 a (e.g. a CD 11 a fragment comprising the "MHM24 epitope", such as CDl la I-domain fragment).
  • cells expressing CDl la at their cell surface can be used to generate antibodies.
  • Such cells can be transformed to express CDl la and, optionally, CD 18 or may be other naturally occurring cells (e.g. human lymphoblastoid cells, see Hildreth etal. Eur. J. Immunol. 13:202- 208 (1983)) or Jurkat cells (see Example below).
  • Other forms of CDl la useful for generating antibodies will be apparent to those skilled in the art.
  • a protein that is immunogenic in the species to be immunized e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin
  • Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 ⁇ g or 5 ⁇ g of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites.
  • the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites.
  • Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
  • the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent.
  • Conjugates also can be made in recombinant cell culture as protein fusions.
  • aggregating agents such as alum are suitably used to enhance the immune response.
  • Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al, Nature, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).
  • a mouse or other appropriate host animal such as a hamster or macaque monkey
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
  • the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase
  • HGPRT the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • hypoxanthine aminopterin
  • HAT medium thymidine
  • Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and M.C.-l 1 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA.
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol, 133:3001 (1984); Brodeur et al, Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al, Anal. Biochem., 107:220 (1980). After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding,
  • Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium.
  • the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below.
  • amino acid changes also may alter post-translational processes of the humanized anti-CDl la antibody, such as changing the number or position of glycosylation sites.
  • a useful method for identification of certain residues or regions of the humanized anti-CDl la antibody polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells Science, 244: 1081-1085 (1989).
  • a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with CDl la antigen.
  • Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • terminal insertions include humanized anti-CDl la antibody with an N-terminal methionyl residue or the antibody fused to an epitope tag.
  • Other insertional variants of the humanized anti-CDl la antibody molecule include the fusion to the N- or C-terminus of humanized anti-CDl la antibody of an enzyme or a polypeptide which increases the serum half-life of the antibody (see below).
  • variants are an amino acid substitution variant. These variants have at least one amino acid residue in the humanized anti-CDl la antibody molecule removed and a different residue inserted in its place.
  • the sites of greatest interest for substitutional mutagenesis include the hypervariable loops, but FR alterations are also contemplated.
  • Table IV in the Example below provides guidance as to hypervariable region residues which can be altered. Hypervariable region residues or FR residues involved in antigen binding are generally substituted in a relatively conservative manner. Such conservative substitutions are shown in Table I under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in Table I, or as further described below in reference to amino acid classes, are introduced and the products screened.
  • Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • Naturally occurring residues are divided into groups based on common side-chain properties: (1) hydrophobic: norleucine, met, ala, val, leu, ile;
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
  • Any cysteine residue not involved in maintaining the proper conformation of the humanized anti- CD 1 1 a antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.
  • cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).
  • Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody.
  • N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue.
  • the tripeptide sequences asparagine-X- serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
  • X is any amino acid except proline
  • O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
  • glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).
  • Nucleic acid molecules encoding amino acid sequence variants of humanized anti-CDl la antibody are prepared by a variety of methods known in the art.
  • These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non- variant version of humanized anti-CD 11 a antibody.
  • amino acid sequence variants of the humanized anti-CDl la antibody will have an amino acid sequence having at least 75% amino acid sequence identity with the original humanized antibody amino acid sequences of either the heavy or the light chain (e.g. as in SEQ ID NO:2 or 5), more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.
  • Identity or homology with respect to this sequence is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the humanized anti-CDl la residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions (as defined in Table I above) as part of the sequence identity. None of N-terminal, C-terminal, or internal extensions, deletions, or insertions into the antibody sequence shall be construed as affecting sequence identity or homology.
  • Antibodies having the characteristics identified herein as being desirable in a humanized anti-CDl la antibody are screened for.
  • epitope mapping e.g. as described in Champe et al, J. Biol. Chem. 270: 1388-1394 (1995), can be performed to determine whether the antibody binds an epitope of interest.
  • Antibody affinities may be determined by saturation binding using either peripheral blood mononuclear cells or rhesus leukocytes as described in the Example below. According to this method for determining antibody affinity, lymphocytes or rhesus leukocytes are added to the plates in a volume of 170 ⁇ l per well and plates are incubated for 2 hr at room. After incubation, cells are harvested and washed 10 times. Samples are then counted. Data is transformed from counts per minute to nanomolarity and four-parameter curve-fitting of saturation plots (bound versus total) are then performed to determine KJ (app) values.
  • Preferred humanized antibodies are those which bind human CDl la with a KJ value of no more than about 1 x 10 " 7; preferably no more than about 1 x 10 " 8 ; more preferably no more than about 1 x 10 " ; and most preferably no more than about 2 x 10 " . It is also desirable to select humanized antibodies which have beneficial anti-adhesion properties in the "keratinocyte monolayer adhesion assay".
  • Preferred antibodies are those which have an IC50 (nM) value of no more than about 250nM; preferably no more than about lOOnM; more preferably no more than about InM and most preferably no more than about 0.5nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1.
  • IC50 (nM) value of no more than about 250nM; preferably no more than about lOOnM; more preferably no more than about InM and most preferably no more than about 0.5nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1.
  • normal human epidermal keratinocytes are removed from culture flasks and resuspended in lymphocyte assay medium at a concentration of 5 x 10 viable cells/ml. Aliquots of 0.1 ml/well are then cultured overnight in flat-bottom 96-well plates; appropriate wells are stimulated by addition of interferon-
  • Jurkat clone E6-1 cells are labeled, washed, resuspended to 1 x 10 cells/ml, and incubated with 2-fold serial dilutions starting at 500ng/ml antibody at 4° C for 30 min. After removal of medium from the keratinocyte monolayer, 0.1 ml/well of labeled cells are added and incubated at 37° C for 1 h. The wells are washed to remove non-attached cells and fluorescence is measured.
  • Desirable humanized anti-CDIIa antibodies are those which have an IC50 (nM) value of no more than about lOOnM; preferably no more than about 50nM; more preferably no more than about 5nM and most preferably no more than about 1 nM in the mixed lymphocyte response (MLR) assay, using human lymphocytes.
  • MLR mixed lymphocyte response
  • peripheral blood lymphocytes from two unrelated donors are isolated from whole, heparinized blood and are resuspended to a concentration of 3 x 10 cells/ml in RPMI 1640 (GIBCO) with additives as described in the Example below.
  • the stimulator cells are made unresponsive by irradiation.
  • Responder cells at a concentration of 1.5 x 10 cells per well are co-cultured with an equal number of stimulator cells in 96-well, flat-bottom plates. Two-fold serial dilutions of antibody starting at a concentration of lOnM are added to the cultures to give a total volume of 200 ⁇ l/well. The cultures are incubated at 37°C in 5% CO2 for 5 days and then pulsed with 1 ⁇ Ci/well of [ 3 H]thymidine for 16 h and [ H]thymidine incorporation is measured.
  • the humanized CD 11 a antibody is an antibody fragment.
  • Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al, Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al, Science 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. For example, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (Carter et al, Bio/Technology 10: 163-167 (1992)). According to another approach, F(ab')2 fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.
  • Multispecific antibodies it may be desirable to generate multispecific (e.g. bispecific) humanized CD 11 a antibodies having binding specificities for at least two different epitopes.
  • Exemplary bispecific antibodies may bind to two different epitopes of the CDl la protein.
  • an anti-CDl la arm may be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g., CD2 or CD3), or Fc receptors for IgG (Fc ⁇ R), such as Fc ⁇ RI (CD64), Fc ⁇ RII (CD32) and Fc ⁇ RIII (CD16) so as to focus cellular defense mechanisms to the CDl la-expressing cell.
  • a triggering molecule such as a T-cell receptor molecule (e.g., CD2 or CD3), or Fc receptors for IgG (Fc ⁇ R), such as Fc ⁇ RI (CD64), Fc ⁇ RII (CD32) and Fc ⁇ RIII (CD16) so
  • Bispecific antibodies may also be used to localize cytotoxic agents to cells which express CDl la. These antibodies possess an CDl la-binding arm and an arm which binds the cytotoxic agent (e.g., saporin, anti-interferon-oc, vinca alkaloid, ricin A chain, methotrexate or radioactive isotope hapten). Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies). According to another approach for making bispecific antibodies, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the Cp j 3 domain of an antibody constant domain.
  • bispecific antibodies include cross-linked or "heteroconjugate" antibodies.
  • one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
  • Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980, along with a number of cross-linking techniques.
  • One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
  • the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
  • T cells as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.
  • bispecific antibodies have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
  • the fragments comprise a heavy-chain variable domain (VJJ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VJJ and V L domains of one fragment are forced to pair with the complementary V L and V j ⁇ domains of another fragment, thereby forming two antigen-binding sites.
  • VJJ heavy-chain variable domain
  • V L light-chain variable domain
  • Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber et al, J. Immunol. 152:5368 (1994).
  • the bispecific antibody may be a "linear antibody” produced as described in Zapata et al. Protein Eng. 8(10): 1057- 1062 (1995). Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al, J. Immunol. 147:60 (1991). (viii) Other modifications
  • humanized anti-CDl la antibody may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance the effectiveness of the antibody in treating cancer, for example.
  • cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al, J. Exp Med. 176: 1 191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992).
  • Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al, Cancer Research 53:2560-2565 (1993).
  • an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al, Anti-Cancer Drug Design 3:219-230 (1989).
  • the invention also pertains to immunoconjugates comprising the antibody described herein conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.
  • a variety of radionuclides are available for the production of radioconjugated anti-CDl la antibodies. Examples include 212 Bi, 13 1 I, 13 1 In, 90 Y and 186 Re.
  • Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p- azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4- dinitrobenzene).
  • SPDP N-succinimidyl-3-(
  • a ricin immunotoxin can be prepared as described in Vitetta et al, Science 238: 1098 (1987).
  • Carbon- 14-labeled l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.
  • the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand” (e.g., avidin) which is conjugated to a cytotoxic agent (e.g., a radio nuclide).
  • a "ligand” e.g., avidin
  • cytotoxic agent e.g., a radio nuclide.
  • the anti-CDl la antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al, Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al, Proc. Natl Acad. Sci. USA 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and
  • Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al, J. Biol. Chem. 257:286-288 (1982) via a disulfide interchange reaction.
  • a chemotherapeutic agent such as Doxorubicin is optionally contained within the liposome. See Gabizon et al, J. National Cancer InstM( ⁇ 9): ⁇ 4%4 (1989)
  • the antibody of the present invention may also be used in ADEPT by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (e.g., a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug.
  • a prodrug e.g., a peptidyl chemotherapeutic agent, see WO81/01145
  • WO 88/07378 See, for example, WO 88/07378 and U.S. Patent No. 4,975,278.
  • the enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to covert it into its more active, cytotoxic form.
  • Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5- fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as ⁇ -galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; ⁇
  • “abzymes” can be used to convert the prodrugs of the invention into free active drugs (see, e.g., Massey, Nature 328:457-458 (1987)).
  • Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.
  • the enzymes of this invention can be covalently bound to the anti-CDl la antibodies by techniques well known in the art such as the use of the heterobifunctional crosslinking reagents discussed above.
  • fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al, Nature 312:604-608 (1984)).
  • an antibody fragment rather than an intact antibody, to increase tumor penetration, for example.
  • the salvage receptor binding epitope generally constitutes a region wherein any one or more amino acid residues from one or two loops of a Fc domain are transferred to an analogous position of the antibody fragment. Even more preferably, three or more residues from one or two loops of the Fc domain are transferred. Still more preferred, the epitope is taken from the CH2 domain of the Fc region (e.g., of an IgG) and transferred to the CHI, CH3, or VJJ region, or more than one such region, of the antibody. Alternatively, the epitope is taken from the CH2 domain of the Fc region and transferred to the C ⁇ region or V L region, or both, of the antibody fragment.
  • the salvage receptor binding epitope comprises the sequence (5' to 3'): PKNSSMISNTP (SEQ ID NO:16), and optionally further comprises a sequence selected from the group consisting of HQSLGTQ (SEQ ID NO: 17), HQNLSDGK (SEQ ID NO: 18), HQNISDGK (SEQ ID NO: 19), or VISSHLGQ (SEQ ID NO:20), particularly where the antibody fragment is a Fab or F(ab') 2 -
  • the salvage receptor binding epitope is a polypeptide containing the sequence(s)(5' to 3'): HQNLSDGK (SEQ ID NO: 18), HQNISDGK (SEQ ID NO: 19), or VISSHLGQ (SEQ ID NO:20) and the sequence: PKNSSMISNTP (SEQ ID NO: 16).
  • Covalent modifications of the humanized CDl la antibody are also included within the scope of this invention. They may be made by chemical synthesis or by enzymatic or chemical cleavage of the antibody, if applicable. Other types of covalent modifications of the antibody are introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.
  • Lysinyl and amino-terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl residues.
  • Other suitable reagents for derivatizing ⁇ -amino-containing residues include imidoesters such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4- pentanedione, and transaminase-catalyzed reaction with glyoxylate.
  • Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK a of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
  • Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides
  • aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
  • Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. These residues are deamidated under neutral or basic conditions. The deamidated form of these residues falls within the scope of this invention.
  • Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the ⁇ -amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79- 86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.
  • Another type of covalent modification involves chemically or enzymatically coupling glycosides to the antibody. These procedures are advantageous in that they do not require production of the antibody in a host cell that has glycosylation capabilities for N- or O-linked glycosylation.
  • the sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine.
  • arginine and histidine arginine and histidine
  • free carboxyl groups such as those of cysteine
  • free hydroxyl groups such as those of serine, threonine, or hydroxyproline
  • aromatic residues such as those of phenylalanine
  • Removal of any carbohydrate moieties present on the antibody may be accomplished chemically or enzymatically.
  • Chemical deglycosylation requires exposure of the antibody to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the antibody intact.
  • Chemical deglycosylation is described by Hakimuddin, et al Arch. Biochem. Biophys. 259:52 (1987) and by Edge et al. Anal. Biochem., 118:131 (1981).
  • Enzymatic cleavage of carbohydrate moieties on antibodies can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al. Meth. Enzymol 138:350 (1987).
  • Another type of covalent modification of the antibody comprises linking the antibody to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
  • the invention also provides isolated nucleic acid encoding the humanized anti-CDl la antibody, vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody.
  • the nucleic acid encoding it is isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression.
  • DNA encoding the monoclonal antibody is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
  • Many vectors are available.
  • the vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
  • the anti-CDl la antibody of this invention may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • a heterologous polypeptide which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • the heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell.
  • the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders.
  • a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders.
  • yeast secretion the native signal sequence may be substituted by, e.g., the yeast invertase leader, a factor leader (including Saccharomyces and Kluyveromyces a -factor leaders), or acid phosphatase leader, the C. albicans glucoamylase leader, or the signal described in WO 90/13646.
  • mammalian signal sequences as well as viral secretory leaders, for example, the herpes simplex gD signal, are available.
  • the DNA for such precursor region is ligated in reading frame to DNA encoding the anti-CDl la antibody.
  • Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells.
  • this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences.
  • origins of replication or autonomously replicating sequences are well known for a variety of bacteria, yeast, and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.
  • the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).
  • Selection genes may contain a selection gene, also termed a selectable marker.
  • Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene produce a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin, mycophenolic acid and hygromycin.
  • suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the anti-CDl la antibody nucleic acid, such as DHFR, thymidine kinase, metallothionein-I and -II, preferably primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, etc.
  • cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR.
  • Mtx methotrexate
  • DHFR Chinese hamster ovary
  • host cells transformed or co-transformed with DNA sequences encoding anti-CDl la antibody, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3'-phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Patent No. 4,965,199.
  • a suitable selection gene for use in yeast is the trp ⁇ gene present in the yeast plasmid YRp7
  • the trp ⁇ gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics,
  • yeast host cell genome provides an effective environment for detecting transformation by growth in the absence of tryptophan.
  • Z,ew2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
  • vectors derived from the 1.6 ⁇ m circular plasmid pKDl can be used for transformation of Kluyveromyces yeasts.
  • an expression system for large-scale production of recombinant calf chymosin was reported for K. lactis. Van den Berg, Bio/Technology, 8:135 (1990).
  • Stable multi-copy expression vectors for secretion of mature recombinant human serum albumin by industrial strains of Kluyveromyces have also been disclosed. Fleer et al, Bio/Technology, 9:968-975 (1991).
  • Promoter component Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the anti-CDl la antibody nucleic acid. Promoters suitable for use with prokaryotic hosts include the phoA promoter , ⁇ -lactamase and lactose promoter systems, alkaline phosphatase, a tryptophan (trp) promoter system, and hybrid promoters such as the tac promoter. However, other known bacterial promoters are suitable. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the anti-CDl la antibody.
  • S.D. Shine-Dalgarno
  • Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CNCAAT region where N may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into eukaryotic expression vectors.
  • suitable promoting sequences for use with yeast hosts include the promoters for 3- phosphoglycerate kinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
  • 3- phosphoglycerate kinase or other glycolytic enzymes such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruv
  • yeast promoters which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3- phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization.
  • Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
  • Yeast enhancers also are advantageously used with yeast promoters.
  • Anti-CDl la antibody transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, from heat-shock promoters, provided such promoters are compatible with the host cell systems.
  • viruses such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus
  • the early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication.
  • the immediate early promoter of the human cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment.
  • a system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. See also Reyes et al, Nature 297:598-601 (1982) on expression of human ⁇ -interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus. Alternatively, the rous sarcoma virus long terminal repeat can be used as the promoter.
  • Enhancer sequences are now known from mammalian genes (globin, elastase, albumin, ⁇ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • the enhancer may be spliced into the vector at a position 5' or 3' to the anti-CDl la antibody-encoding sequence, but is preferably located at a site 5' from the promoter.
  • Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding anti- CDl la antibody.
  • One useful transcription termination component is the bovine growth hormone polyadenylation region. See W094/11026 and the expression vector disclosed therein.
  • Suitable host cells for cloning or expressing the DNA in the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above.
  • Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B.
  • Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus
  • Salmonella e.g., Salmonella typhimurium
  • Serratia e.g.,
  • E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. co/ X1776 (ATCC 31,537), and £. coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-CD 11 a antibody-encoding vectors.
  • Saccharomyces cerevisiae, or common baker's yeast is the most commonly used among lower eukaryotic host microorganisms.
  • a number of other genera, species, and strains are commonly available and useful herein, such as Schizosaccharomyces pombe;
  • Kluyveromyces hosts such as, e.g., K lactis, K fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), AT. thermotolerans, and K marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070); Candida; Trichoderma reesia (EP
  • Neurospora crassa Schwanniomyces such as Schwanniomyces occidentalis
  • filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and /4, niger.
  • Suitable host cells for the expression of glycosylated anti-CDl la antibody are derived from multicellular organisms.
  • invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda
  • Bombyx mori have been identified.
  • a variety of viral strains for transfection are publicly available, e.g., the
  • L-l variant of Autographa califo nica NPV and the Bm-5 strain of Bombyx mori NPV may be used as the virus herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells.
  • Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts.
  • vertebrate cells have been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure.
  • useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al, J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al, Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod.
  • monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51 ); TRI cells (Mather et al, Annals N. Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).
  • Host cells are transformed with the above-described expression or cloning vectors for anti-CDl la antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • Culturing the host cells The host cells used to produce the anti-CDl la antibody of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al, Meth.
  • any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCINTMdrug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
  • the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • the antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter et al, Bio/Technology 10:163-167 (1992) describe a procedure for isolating antibodies which are secreted to the periplasmic space of E. coli.
  • cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min.
  • PMSF phenylmethylsulfonylfluoride
  • Cell debris can be removed by centrifugation.
  • supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • a protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • the antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique.
  • affinity chromatography is the preferred purification technique.
  • the suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody.
  • Protein A can be used to purify antibodies that are based on human ⁇ 1, ⁇ 2, or ⁇ 4 heavy chains (Lindmark et al, J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human ⁇ 3 (Guss et al, EMBO J. 5: 15671575 (1986)).
  • the matrix to which the affinity ligand is attached is most often agarose, but other matrices are available.
  • Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose.
  • the antibody comprises a C j ⁇ 3 domain
  • the Bakerbond ABXTMresin J. T. Baker, Phillipsburg, NJ
  • the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g.,from about 0-0.25M salt).
  • elution buffer at a pH between about 2.5-4.5, preferably performed at low salt concentrations (e.g.,from about 0-0.25M salt).
  • Therapeutic formulations of the antibody are prepared for storage by mixing the antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldunethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine
  • the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • active compound preferably those with complementary activities that do not adversely affect each other.
  • it may be desirable to further provide an immunosuppressive agent. 1
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • the active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • macroemulsions for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
  • Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
  • copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate non-degradable ethylene- vinyl acetate
  • degradable lactic acid-glycolic acid copolymers such as the Lupron DepotTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)
  • poly-D-(-)-3- hydroxybutyric acid While polymers such as ethylene- vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • encapsulated antibodies When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
  • the antibodies of the invention may be used as affinity purification agents.
  • the antibodies are immobilized on a solid phase such a Sephadex resin or filter paper, using methods well known in the art.
  • the immobilized antibody is contacted with a sample containing the CDl la protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the CDl la protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the CDl la protein from the antibody.
  • Anti-CDl la antibodies may also be useful in diagnostic assays for CDl la protein, e.g., detecting its expression in specific cells, tissues, or serum.
  • the antibody typically will be labeled with a detectable moiety.
  • a detectable moiety Numerous labels are available which can be generally grouped into the following categories:
  • Radioisotopes such as 35 S, 14 C, 125 I, 3 H, and 13 1 I.
  • the antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al, Ed. Wiley-Interscience, New York, New York, Pubs. (1991) for example and radioactivity can be measured using scintillation counting.
  • Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin and Texas Red are available.
  • the fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a fluorimeter.
  • the enzyme generally catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above.
  • the chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor.
  • enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent
  • Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym. (ed J. Langone & H.
  • enzyme-substrate combinations include, for example:
  • HRPO Horseradish peroxidase
  • HPO horseradish peroxidase
  • OPD orthophenylene diamine
  • TMB 3,3',5,5'-tetramethyl benzidine hydrochloride
  • ⁇ -D-galactosidase ( ⁇ -D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl- ⁇ -D- galactosidase) or fluorogenic substrate 4-methylumbelliferyl- ⁇ -D-galactosidase.
  • a chromogenic substrate e.g., p-nitrophenyl- ⁇ -D- galactosidase
  • fluorogenic substrate 4-methylumbelliferyl- ⁇ -D-galactosidase 4-methylumbelliferyl- ⁇ -D-galactosidase.
  • the label is indirectly conjugated with the antibody.
  • the antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner.
  • the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody).
  • the anti-CDl la antibody need not be labeled, and the presence thereof can be detected using a labeled antibody which binds to the CDl la antibody.
  • the antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques, pp.147-158 (CRC Press, Inc. 1987).
  • Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody.
  • the amount of CDl la protein in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies.
  • the antibodies generally are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.
  • Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected.
  • the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex.
  • the second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay).
  • sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.
  • the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.
  • the antibodies may also be used for in vivo diagnostic assays.
  • the antibody is labeled with a radio nuclide (such as * 1 'in, 99 Tc, 14 C, l3 , 125 1, 3 H, 32 P or 35 S) so that the tumor can be localized using immunoscintiography.
  • a radio nuclide such as * 1 'in, 99 Tc, 14 C, l3 , 125 1, 3 H, 32 P or 35 S
  • the antibody of the present invention can be provided in a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic assay.
  • the kit will include substrates and cofactors required by the enzyme (e.g, a substrate precursor which provides the detectable chromophore or fluorophore).
  • substrates and cofactors required by the enzyme e.g, a substrate precursor which provides the detectable chromophore or fluorophore
  • other additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer) and the like.
  • the relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents which substantially optimize the sensitivity of the assay.
  • the reagents may be provided as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.
  • the anti-CDl la antibody of the present invention may be used to treat the various LFA-1 mediated disorders as described herein.
  • the anti-CDl la antibody is administered by any suitable means, including parenteral, subcutaneous, infraperitoneal, intrapulmonary, and intranasal, and, if desired for local immunosuppressive treatment, intralesional administration (including perfusing or otherwise contacting the graft with the antibody before transplantation).
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
  • the anti-CDl la antibody is suitably administered by pulse infusion, particularly with declining doses of the antibody.
  • the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
  • the appropriate dosage of antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
  • the antibody is suitably administered to the patient at one time or over a series of treatments.
  • ⁇ g/kg to 15 mg/kg (e.g., 0.1 -20mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
  • a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above.
  • the treatment is sustained until a desired suppression of disease symptoms occurs.
  • other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
  • An exemplary dosing regimen is disclosed in WO 94/04188.
  • the antibody composition will be formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the "therapeutically effective amount" of the antibody to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat the LFA-1 -mediated disorder, including treating rheumatoid arthritis, reducing inflammatory responses, inducing tolerance of unmunostimulants, preventing an immune response that would result in rejection of a graft by a host or vice-versa, or prolonging survival of a transplanted graft.
  • Such amount is preferably below the amount that is toxic to the host or renders the host significantly more susceptible to infections.
  • the antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question.
  • the antibody may be given in conjunction with a glucocorticosteroid.
  • T cell receptor peptide therapy is suitably an adjunct therapy to prevent clinical signs of autoimmune encephalomyelitis.
  • the antibody may be administered concurrently with or separate from an immunosuppressive agent as defined above, e.g., cyclosporin A, to modulate the immunosuppressant effect.
  • an immunosuppressive agent as defined above, e.g., cyclosporin A
  • VLA-4 antagonists or other LFA-1 antagonists may be administered to the mammal suffering from a LFA-1 mediated disorder.
  • the effective amount of such other agents depends on the amount of anti-CDl la antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.
  • an article of manufacture containing materials useful for the treatment of the disorders described above comprises a container and a label.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the active agent in the composition is the anti-CDl la antibody.
  • the label on, or associated with, the container indicates that the composition is used for treating the condition of choice.
  • the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • a pharmaceutically-acceptable buffer such as phosphate-buffered saline, Ringer's solution and dextrose solution.
  • It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • Both the murine and humanized MAbs effectively prevent adhesion of human T cells to human keratinocytes and the proliferation of T cells in response to nonautologous leukocytes in the mixed lymphocytes response (MLR), a model for responsiveness to MHC class II antigens (McCabe et al, Cellular Immunol. 150:364-375 (1993)).
  • MLR mixed lymphocytes response
  • both the murine (Reimann et al, Cytometry, 17:102-108 (1994)) and humanized MAbs did not cross-react with nonhuman primate CDl la other than chimpanzee CDl la.
  • the humanized MAb was re-engineered to bind to rhesus CDl la by changing four residues in one of the complementarity-determining regions, CDR-H2, in the variable heavy domain.
  • Cloning and molecular modeling of the rhesus CDl la I-domain suggested that a change from a lysine residue in human CDl la I-domain to glutamic acid in rhesus CDl la I-domain is the reason that the murine and humanized MAbs do not bind rhesus CDl la.
  • the murine anti-human CDl la MAb, MHM24 (Hildreth etal, Eur. J. Immunol. 13:202-208 (1983); Hildreth et al, J. Immunol. 134:3272-3280 (1985)), was cloned and sequenced.
  • the phagemid pEMXl was constructed.
  • pEMXl contains a DNA fragment encoding a humanized K-subgroup I light chain and a humanized subgroup III heavy chain (VH-CH1) and an alkaline phosphatase promotor and Shine-Dalgarno sequence both derived from another previously described pUCl 19-based plasmid, pAK2 (Carter et al, Proc. Natl. Acad. Sci. USA 89:4285 (1992)).
  • VH-CH1 humanized K-subgroup I light chain
  • pAK2 alkaline phosphatase promotor and Shine-Dalgarno sequence
  • F(ab)- 1 site-directed mutagenesis (Kunkel, Proc. Natl. Acad. Sci. USA 82:488 (1985)) was performed on a deoxyuridine-containing template of pEMXl; all six CDRs were changed to the MHM24 sequence. All other F(ab) variants were constructed from a template of F(ab)-1. Plasmids were transformed into E. coli strain XL-1 Blue (Stratagene, San Diego, CA) for preparation of double- and single-stranded DNA.
  • APS media consists of : 1.5 g glucose, 11.0 Hycase SF, 0.6 g yeast extract (certified), 0.19 g MgS04 (anhydrous), 1.07 g NH4C1, 3.73 g KC1, 1.2 g NaCl, 120 ml 1 M triethanolamine, pH 7.4, to 1 L water and then sterile filtered through 0.1 ⁇ m Sealkeen filter.
  • Cells were harvested by centrifugation in a 1 L centrifuge bottle (Nalgene) at 3000 x g and the supernatant removed. After freezing for 1 h, the pellet was resuspended in 25 ml cold 10 mM MES-10 mM EDTA, pH 5.0 (buffer A). 250 ⁇ l of0.1 M PMSF (Sigma) was added to mhibit proteolysis and 3.5 ml of stock 10 mg/ml hen egg white lysozyme (Sigma) was added to aid lysis of the bacterial cell wall. After gentle shaking on ice for 1 h, the sample was centrifuged at 40,000 x g for 15 min.
  • the supernatant was brought to 50 ml with buffer A and loaded onto a 2 ml DEAE column equilibrated with buffer A.
  • the flow-through was then applied to a protein G-Sepharose CL-4B (Pharmacia) column (0.5 ml bed volume) equilibrated with buffer A.
  • the column was washed with 10 ml buffer A and eluted with 3 ml 0.3 M glycine, pH 3.0, into 1.25 ml 1 M Tris, pH 8.0.
  • the F(ab) was then buffer exchanged into PBS using a Centricon-30 (Amicon) and concentrated to a final volume of 0.5 ml.
  • Heavy and light chain plasmids were cotransfected into an adenovirus-transformed human embryonic kidney cell line, 293 (Graham et al, J. Gen. Virol. 36:59 (1977)), using a high efficiency procedure (Graham et al, J. Gen. Virol. 36:59 (1977); Gorman et al, Science, 221:551 (1983)). Media was changed to serum-free and harvested daily for up to 5 days. Antibodies were purified from the pooled supernatants using protein A- Sepharose CL-4B (Pharmacia). The eluted antibody was buffer exchanged into PBS using a Centricon-30 (Amicon), concentrated to 0.5 ml, sterile filtered using a Millex-GV (Millipore) and stored at 4°C.
  • the concentration of antibody was determined using total Ig-binding ELISA.
  • the concentration of the reference humanized anti-pl85 HER IgGl was determined by amino acid composition analysis.
  • Each well of a 96-well plate was coated with 1 ⁇ g/ml of goat anti-human IgG F(ab')2 (Cappel Laboratories, Westchester, PA) for 24 h at 4°C. Purified antibodies were diluted and added in duplicate to the coated plates.
  • the DNA sequence of the rhesus I-domain was obtained using RT-PCR and primers derived from the ⁇ human CDl la DNA sequence. Briefly, mRNA was isolated from ⁇ 10 rhesus leukocytes using the Fast Track mRNA purification kit (Invitrogen). 10 ⁇ g mRNA was reverse transcribed using MuLV reverse transcriptase. The first strand cDNA was then amplified by 40 cycles of PCR using the primers: 5'-CACTTTGGATACCGCGTCCTGCAGGT-3' (forward) (SEQ ID NO:21) and 5'-CATCCTGCAGGTCTGCCTTCAGGTCA-3' (reverse) (SEQ ID NO:22).
  • a single band of the predicted size was purified from the PCR reaction using agarose gel electrophoresis.
  • the PCR product was digested with restriction enzyme Sse8387I (Takara) and ligated to a human CDl la-containing plasmid digested with the same restriction enzyme. There are two Sse8387I sites in the human CDl la sequence, one on either side of the I-domain.
  • DNA sequence analysis revealed five amino acid differences between human and rhesus. One difference was in the region N- terminal to the I-domain (Thr59Ser) and the other four differences were in the I-domain itself: Vall33Ile, Argl89Gln, Lysl97Glu, and Val308Ala (Fig. 2).
  • Radiolabeled antibodies were prepared using Iodo-Gen (Pierce, Rockford, IL) according to the manufacturer's instructions. 50 ⁇ g of antibody and 1 mCi I (DuPont, Wilmington, DE) were added to each tube and incubated for 15 min at 25° C. Radiolabeled proteins were purified from the remaining free I using PD-10 columns (Pharmacia, Uppsala, Sweden) equilibrated in Hank's Balanced Salt Solution (HBSS, Life Technologies, Grand Island, NY) containing 0.2% gelatin.
  • HBSS Hank's Balanced Salt Solution
  • Mononuclear cells were purified from heparinized human peripheral blood collected from two donors using Lymphocyte Separation Medium (LSM, Organon Teknika, Durham, NC) according to the manufacturer's instructions. The blood was centrifuged at 400 x g for 40 min at 25° C with no braking. Cells at the interface of the LSM and plasma were harvested and then resuspended in HBSS-0.2% gelatin. Leukocytes were purified from heparinized rhesus monkey peripheral blood collected from two individuals by Dextran sedimentation. Blood was diluted with an equal volume of 3% Dextran T500 (Pharmacia) in PBS and was allowed to sediment undisturbed at 25° C for 30 min.
  • LSM Lymphocyte Separation Medium
  • erythrocytes were removed by two cycles of hypotonic lysis using distilled water and 2X HBSS. After erythrocyte lysis, cells were washed in PBS and then resuspended in HBSS-0.2% gelatin.
  • Antibody affinities were determined by saturation binding using either peripheral blood mononuclear cells (murine MHM24 and HulgG 1) or rhesus leukocytes (MHM23, RhlgGl).
  • a radiolabeled antibody was serially diluted in HBSS-0.2% gelatin in quadruplicate. Nonspecific binding was determined by the addition of 500nM final concentration of homologous unlabeled antibody in duplicate through the serial dilution.
  • Human lymphocytes or rhesus leukocytes were added to the plates in a volume of 170 ⁇ l per well. Plates were incubated for 2 hr at room temperature on an orbital plate shaker.
  • Keratinocyte monolayer adhesion assay Normal human epidermal keratinocytes (Clonetics, San Diego, CA) were removed from culture flasks with trypsin-EDTA, centrifuged, and resuspended in lymphocyte assay medium (RPMI 1640 (GIBCO)-10% fetal calf serum-1% penicillin/streptomycin) at a concentration of 5 x 10 viable cells/ml. Aliquots of 0.1 ml/well were then cultured overnight in flat-bottom 96-well plates; appropriate wells were stimulated by addition of interferon-gamma (Genentech, South San Francisco, CA) at 100 units/well.
  • RPMI 1640 fetal calf serum-1% penicillin/streptomycin
  • Jurkat clone E6-1 cells ATCC, Rockville, MD
  • purified rhesus lymphocytes see MLR methods
  • 20 ⁇ g/ml Calcein AM Molecular Probes, Eugene, OR
  • Jurkat or rhesus lymphocyte cells were resuspended to 1 x 10 cells/ml and incubated with serially-diluted antibody at 4°C for 30 min.
  • 0.1 ml/well oflabeled cells were added and incubated at 37°C for 1 h.
  • the wells were washed five times with 0.2 ml/well/wash of 37° C lymphocyte medium to remove non-attached cells. Fluorescence was measured using a Cytofluor 2300 (Millipore, Bedford, MA).
  • a rhesus-human chimeric CDl la (Rh/HuCDl la) comDrising human CDl la with a rhesus I-domain was constructed by site-directed mutagenesis (Kunkel, Proc. Natl Acad. Sci. USA 82:488 (1985)) on a deoxyuridine-containing template plasmid encoding human CDl la. Four residues were altered: Vall33Ile, Argl89Gln, Lysl97Glu, and Val308Ala (Fig. 2).
  • Rh/HuCDl la and human CDl lb Plasmids coding for Rh/HuCDl la and human CDl lb (EP 364, 690) were cotransfected into an adenovirus-transformed human embryonic kidney cell line, 293 (Graham et al, J. Gen. Virol. 36:59 (1977)), using a high efficiency procedure (Graham et al, J. Gen. Virol. 36:59 (1977); Gorman et al, Science, 221 :551 (1983)). Rh/HuCDl la-transfected 293 cells were labeled with 20 ⁇ g/ml Calcein AM at 37° C for 45 min.
  • Rh/HuCDl la-transfected 293 cells were resuspended to 1 x 10 cells/ml and incubated with serially-diluted antibody at 4° C for 30 min. After removal of medium from the keratinocyte monolayer, 0.1 ml/well oflabeled 293 cells was added and incubated at 37° C for 1 h. The wells were washed five times with 0.2 ml/well/wash of 37° C lymphocyte medium to remove non-attached cells. Fluorescence was measured using a Cytofluor 2300. (g) ICAM adhesion assay
  • the ICAM-IgG consisted of the five extracellular domains of human ICAM fused onto a human IgG Fc.
  • a plasmid for the expression of a human ICAM-1 (Simmons et al. Cell 331 :624-627 (1988) and Staunton et al. Cell 52:925-933 (1988)) immunoadhesin called pRK.5dICAMGaIg was constructed. It contains the five Ig-like domains of ICAM-1, a six amino acid cleavage site recognized by an H64A variant of subtilisin BPN', Genenase I (Carter et al.
  • a clone was selected which expressed 20 ⁇ g/ml of secreted 5dICAMIg by enzyme-linked immunosorbent assay (ELISA), using antibodies to human IgG Fc (Caltag, Burlingame, CA) and ICAM-1 (BBIG-I1; R & D Systems, Minneapolis, MN).
  • ELISA enzyme-linked immunosorbent assay
  • Cell culture supernatant from this cell line was loaded onto a Protein A column (ProsepA, Bioprocessing, Ltd., Durham, England) equilibrated in 0.01 M Hepes buffer (pH 7.0), 0.15 M NaCl (HBS) and the column was washed with HBS followed by 0.01 M Hepes buffer (pH 7.0), 0.5 M NaCl, 0.5 M TMAC (tetra-methyl ammonium chloride) to remove non-specifically bound material.
  • the TMAC buffer was thoroughly washed from the column with HBS and the 5dICAMIg eluted with 0.01 M Hepes buffer (pH 7.0), 3.5 M M MgC12 and 10% (w/v) glycerol.
  • the protein A pool was dialyzed extensively against HBS and concentrated.
  • rhesus lymphocytes were labeled with 20 ⁇ g/ml Calcein AM (Molecular Probes, Eugene, OR) at 37° C for 45 min. After washing three times with lymphocyte assay medium, rhesus lymphocyte cells were resuspended to 1 x 10 cells/ml and incubated with serially-diluted antibody at 4°C for 30 min. After removal of medium from the ICAM-IgG coated plates, 0.1 ml/well of labeled cells were added and incubated at 37° C for 1 h. The wells were washed five times with 0.2 ml well/wash of 37° C lymphocyte medium to remove non-attached cells. Fluorescence was measured using a Cytofluor 2300 (Millipore, Bedford, MA).
  • Lymphocyte Separation Medium (Organon Teknika, Durham, NC). Lymphocytes were resuspended to a concentration of 3 x 10 cells/ml in RPMI 1640 (GIBCO)-10% human AB serum- 1 % glutamine- 1 % penicillin/streptomycin- 1 % non-essential amino acids- 1 % pyruvate-5 x 10 " M 2- ⁇ -mercaptoethanol-50 ⁇ g/ml gentamycin-5 ⁇ g/ml polymyxin B.
  • the stimulator cells were made unresponsive by irradiation with 3000 rads in a cesium irradiator.
  • Responder cells at a concentration of 1.5 x 10 cells per well were co-cultured with an equal number of stimulator cells in 96-well, flat-bottom plates.
  • Serial two-fold dilutions of each antibody were added to the cultures to give a total volume of 200 ⁇ l/well.
  • the cultures were incubated at 37° C in 5% C02 for 5 days and then pulsed with 1 ⁇ Ci/well of [ J H]thymidine for 16 h.
  • [ H]thymidine inco ⁇ oration was measured with a Beckman scintillation counter. Assays were done in triplicate.
  • a humanized anti-human pl85 HER2 MAb (Carter et al, Proc. Natl. Acad. Sci. USA 89:4285 (1992)) was used as isotype control for HulgG 1 and RhlgGl .
  • a murine anti-hamster tPA MAb (Genentech) was used as isotype control (murine IgG 1 ) for the MHM23 MAb.
  • MAb 25.3 was purchased from Immunotech, Inc. (Westbrook, ME).
  • CDR-H1 included residues H28-H35, which includes all exposed residues from both Kabat et al,
  • Murine residues are in bold; residue numbers are according to Kabat et al, Sequences of Proteins of Immunological Interest 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).
  • Mean and standard deviation are the average of the ratios calculated for each of the independent FACScan assays; the EC50 for F(ab)-2 was 771 ⁇ 320 ng/ml.
  • c HulgG 1 is F(ab)-8 VL and VH domains fused to human constant light and heavy chains.
  • chlgGl is chimeric IgG with murine VL and VH domains fused to human constant light and heavy chains.
  • CDR-H2 was extended to include the sequence-based definition (i.e., including residues H60-H65).
  • the EC50 for F(ab)-2 binding to human CDl la was 771 ⁇ 320 ng/ml, which was 148-fold weaker than the EC50 of the chimeric IgGl (5.2 ⁇ 3.0 ng/ml).
  • residues in a framework loop (FR-3) adjacent to CDR-H1 and CDR-H2 can affect binding (Eigenbrot et al, Proteins 18:49-62 (1994)).
  • F(ab)-5 three residues in this loop were changed to their murine counte ⁇ art and this variant showed a 23-fold improvement in binding (Table II).
  • the VL and VH domains from F(ab)-8 were transferred to human IgGl constant domains.
  • the full length intact antibody, HulgG 1 showed an EC50 equivalent to F(ab)-8 and improved compared to the full length chimeric IgGl (Table II).
  • Saturation binding analysis was also performed to determine the apparent dissociation constants, K d (app): 0.15 ⁇ 0.02 nM for murine MHM24 and 0.15 ⁇ 0.04 nM for HulgG 1 (Table III).
  • Table III Apparent KJ by saturation binding to human lymphocytes and rhesus leukocytes
  • a CDRs and FR-3 are as defined in Kabat et al, (1991) supra.
  • e hu4D5 is a humanized anti-pl851TFR2 antibody with the same IgGl framework as the huMHM24 antibody
  • CDR-H2 and CDR-H3 are the prominent contributors to the binding.
  • CDR-H1 residue T ⁇ H33Ala had a large effect but this is most likely due to a conformational change as T ⁇ H33 should be partially buried.
  • the most important single residue contributing to the binding is AspH54 in CDR-H2; changing this residue to alanine effected a 147-fold reduction in binding (Table IV).
  • Other residues in CDR-H2 involved in binding include GluH56, GlnH61 and LysH64 (Table IV).
  • TyrH97Ala reduced binding by 11-fold and TyrHlOOcAla by 8-fold.
  • variant H2 bound 18-fold better to rhesus CD 11 a than HulgG 1 (Table IV).
  • individual mutations at the three residues included in variant H2 showed minimal improvement in binding: HisH52Ala, 0.7-fold better, SerH53Ala, 0.7-fold better, and SerH55Ala, 1.3-fold worse (Table IV).
  • position H54 was substituted with a variety of amino acids.
  • H52 and H53 were alanine.
  • position H54 was Asn and position H56 was Glu (original), Ala, Asn or Gin. None of these variants improved rhesus CDl la binding over the H2A1 variant (Table VI).
  • position H54 was Ala and position H56 was Glu (original), Ala, Ser or Asn and again all were worse than variant H2A1.
  • position H54 was Ser and position H56 was Glu (original), Ala, Ser or Asn.
  • Murine MHM24, chimeric IgGl and HuIgGl were compared in their ability to prevent adhesion of Jurkat cells (human T-cells expressing LFA-1) to normal human epidermal keratinocytes expressing ICAM-1. All three antibodies performed similarly (Fig. 3) with similar IC50 values (Table VII).
  • HuK normal human epidermal keratinocyte.
  • RhLy rhesus lymphocyte.
  • HuICAM recombinant human ICAM- 1.
  • Rh/HuCDl la human CDl la with rhesus I-domain transfected into human 293 cells.
  • RhlgGl was compared to the murine anti-human CD 18 antibody MHM23 (Hildreth et al, Eur. J. Immunol. 13:202-208 (1983); Hildreth et al, J. Immunol. 134:3272-3280 (1985)) in blocking adherence of rhesus lymphocytes to human keratinocytes, RhlgGl was 74-fold less efficacious than MHM23 (Fig. 4A, Table VII).
  • RhlgGl was only 4-fold less efficacious than MHM23 (Fig. 4B, Table VII).
  • a chimeric CDl la comprised of human CDl la in which the I-domain was mutated to rhesus (Vall33Ile, Argl89Gln, Lysl97Glu, Val308Ala) was transfected into human embryonic kidney 293 cells.
  • RhlgGl was only 4-fold down from MHM23 in blocking these Rh/HuCDl la-293 cells from adhering to human keratinocytes (Fig. 4C, Table VII).
  • RhlgGl humanized anti-pl85HER2 antibody; Carter et al, Proc. Natl. Acad. Sci. USA 89:4285 (1992)
  • MHM23 murine MAb 354, a murine IgG 1 anti-hamster tPA
  • Rh/HuCDl la to human keratinocytes (Fig. 4C).
  • the recombinant human ICAM-1 data show that RhlgGl is binding to the rhesus lymphocytes and preventing adherence almost as well as murine MHM23 (Fig. 4B, Table VII).
  • the Rh/HuCDl la-293 data (Fig. 4C,
  • Table VII show that RhlgGl is not binding to targets on the human keratinocytes (compared to HuIgGl), which might reduce the concentration of RhlgGl available for binding to rhesus CDl la.
  • the K (app) of RhlgGl to rhesus leukocytes was similar with (rhesus donor 3) and without (rhesus donor 1) addition of 1 mg/ml human IgGl (Table III); This shows that binding of RhlgGl is specific to rhesus CDl la.
  • RhlgGl rhesus-binding variant RhlgGl exhibited an IC50 value slightly better than murine MHM23 (Table VIII).
  • Different responde ⁇ stimulator blood donors were used in independent assays and the results did not vary significantly.
  • the K d of RhlgGl for rhesus CDl la is about 26-fold down from the K d of HuIgGl for human CDl la (Table III) and this is reflected in the IC50 values derived from the MLR assays (Table VIII).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/US1997/019041 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES WO1998023761A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE1997629209 DE122004000047I2 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen CD11A
DE200412000047 DE122004000047I1 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen cd11a.
IL13014397A IL130143A0 (en) 1996-11-27 1997-10-20 Humanized anti-CD11a antibodies
DE69729209T DE69729209T2 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen cd11a
CA2272842A CA2272842C (en) 1996-11-27 1997-10-20 Humanized anti-cd11a antibodies
AU49929/97A AU731817C (en) 1996-11-27 1997-10-20 Humanized anti-CD11a antibodies
EP97912841A EP0941344B1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES
AT97912841T ATE267257T1 (de) 1996-11-27 1997-10-20 Humanisierte anti-koerper gegen cd11a
JP52464598A JP3778945B2 (ja) 1996-11-27 1997-10-20 ヒト化抗ＣＤ１１ａ抗体
KR10-1999-7004671A KR100532178B1 (ko) 1996-11-27 1997-10-20 인간화 항-ＣＤ11ａ 항체
IL130143A IL130143A (en) 1996-11-27 1999-05-26 Humanized antibodies to 11CDa that include a variable region in which non-human antibody amino acids
LU91122C LU91122I2 (fr) 1996-11-27 2004-11-10 Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
NL300163C NL300163I2 (nl) 1996-11-27 2004-11-12 Vermenselijkte anti-CD1 11a-antilichamen.
FR04C0028C FR04C0028I2 (enrdf_load_stackoverflow) 1996-11-27 2004-12-10
IL175583A IL175583A0 (en) 1996-11-27 2006-05-11 HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27
US08/757,205 1996-11-27

Publications (1)

Publication Number Publication Date
WO1998023761A1 true WO1998023761A1 (en) 1998-06-04

Family

ID=25046834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019041 WO1998023761A1 (en) 1996-11-27 1997-10-20 HUMANIZED ANTI-CD11a ANTIBODIES

Country Status (17)

Country Link
EP (2) EP0941344B1 (enrdf_load_stackoverflow)
JP (2) JP3778945B2 (enrdf_load_stackoverflow)
KR (1) KR100532178B1 (enrdf_load_stackoverflow)
AR (1) AR008919A1 (enrdf_load_stackoverflow)
AT (1) ATE267257T1 (enrdf_load_stackoverflow)
AU (1) AU731817C (enrdf_load_stackoverflow)
CA (1) CA2272842C (enrdf_load_stackoverflow)
DE (3) DE122004000047I1 (enrdf_load_stackoverflow)
DK (2) DK0941344T3 (enrdf_load_stackoverflow)
ES (1) ES2221045T3 (enrdf_load_stackoverflow)
FR (1) FR04C0028I2 (enrdf_load_stackoverflow)
IL (3) IL130143A0 (enrdf_load_stackoverflow)
LU (1) LU91122I2 (enrdf_load_stackoverflow)
NL (1) NL300163I2 (enrdf_load_stackoverflow)
PT (1) PT941344E (enrdf_load_stackoverflow)
WO (1) WO1998023761A1 (enrdf_load_stackoverflow)
ZA (1) ZA979599B (enrdf_load_stackoverflow)

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056363A1 (en) * 1999-03-19 2000-09-28 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
WO2001043773A1 (en) * 1999-12-14 2001-06-21 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
US6632926B1 (en) 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants
WO2005016968A2 (en) 2003-07-28 2005-02-24 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
WO2005123777A3 (en) * 2004-06-09 2006-03-02 Genentech Inc Method of treating granuloma annulare or sarcoid
US7060492B2 (en) 2000-10-30 2006-06-13 Vbi Technologies, L.L.C. Isolation of spore-like cells from tissues exposed to extreme conditions
US7214776B2 (en) 1999-01-21 2007-05-08 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7323553B2 (en) 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
EP1950300A2 (en) 1998-11-18 2008-07-30 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP2048154A1 (en) 2002-02-05 2009-04-15 Genentech, Inc. Protein purification
WO2009058812A1 (en) 2007-10-30 2009-05-07 Genentech, Inc. Antibody purification by cation exchange chromatography
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
WO2010099273A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
US7927591B2 (en) * 2004-02-19 2011-04-19 The Cbr Institute For Biomedical Research, Inc. Conformation specific antibodies
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP2371388A2 (en) 2004-10-20 2011-10-05 Genentech, Inc. Antibody formulations
EP2377527A1 (en) 2007-01-22 2011-10-19 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US20110305691A1 (en) * 2000-09-01 2011-12-15 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
WO2011163458A2 (en) 2010-06-24 2011-12-29 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
EP2586788A1 (en) 2007-07-09 2013-05-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2013096322A1 (en) 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
WO2013148249A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Improved harvest operations for recombinant proteins
US8551775B2 (en) 2009-11-12 2013-10-08 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
US20130309244A1 (en) * 2010-12-21 2013-11-21 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2013173687A1 (en) 2012-05-18 2013-11-21 Genentech, Inc. High-concentration monoclonal antibody formulations
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
US8858950B2 (en) 2002-11-27 2014-10-14 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2015006504A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
EP2848625A1 (en) 2008-08-14 2015-03-18 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US9090930B2 (en) 2006-06-27 2015-07-28 Emd Millipore Corporation Method and unit for preparing a sample for the microbiological analysis of a liquid
WO2016007752A1 (en) 2014-07-09 2016-01-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
US9376464B2 (en) 2006-12-21 2016-06-28 Emd Millipore Corporation Purification of proteins
WO2017172994A1 (en) 2016-03-29 2017-10-05 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
US9803165B2 (en) 2008-12-16 2017-10-31 Emd Millipore Corporation Stirred tank reactor and method
WO2018119312A1 (en) 2016-12-22 2018-06-28 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US10233211B2 (en) 2006-12-21 2019-03-19 Emd Millipore Corporation Purification of proteins
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
WO2020010080A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
US10723788B2 (en) 2015-11-24 2020-07-28 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
US10793593B2 (en) 2006-12-21 2020-10-06 Emd Millipore Corporation Purification of proteins
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
US11028148B2 (en) 2017-09-28 2021-06-08 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11168126B2 (en) 2019-04-12 2021-11-09 Geltor, Inc. Recombinant elastin and production thereof
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270439B2 (en) 2002-09-11 2009-09-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
MXPA05011406A (es) * 2003-04-23 2005-12-12 Medarex Inc Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
JP5770624B2 (ja) 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
KR20250007687A (ko) 2013-07-16 2025-01-14 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
RS66328B1 (sr) 2015-09-25 2025-01-31 Hoffmann La Roche Anti-tigit antitela i postupci primene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440351A2 (en) * 1990-01-19 1991-08-07 Merck & Co. Inc. Recombinant human anti-CD18 antibodies
WO1996032478A1 (en) * 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440351A2 (en) * 1990-01-19 1991-08-07 Merck & Co. Inc. Recombinant human anti-CD18 antibodies
WO1996032478A1 (en) * 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. EDWARDS ET AL.: "Identification of amino acids in the CD11a I-domain important for binding of the leukocyte function-associated antigen (LFA-1) to intercellular adhesion molecule-1 (ICAM-1).", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 21, 26 May 1995 (1995-05-26), BALTIMORE, MD, USA, pages 12635 - 12640, XP002054056 *
J. HILDRETH ET AL.: "A human lymphocyte-associated antigen involved in cell-mediated lympholysis.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 13, no. 3, March 1983 (1983-03-01), WEINHEIM, GERMANY, pages 202 - 208, XP002054055 *
P. CARTER ET AL.: "Humanization of an anti-p185HER2 antibody for human cancer therapy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 89, no. 10, May 1992 (1992-05-01), WASHINGTON, DC, USA, pages 4285 - 4289, XP000275844 *
W. WERTHER ET AL.: "Humanization of an anti-lymphocyte function-associated antigen (LFA-1) monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.", THE JOURNAL OF IMMUNOLOGY, vol. 157, no. 11, 1 December 1996 (1996-12-01), BALTIMORE, MD, USA, pages 4986 - 4995, XP002054057 *

Cited By (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703133B2 (en) 1998-11-18 2014-04-22 Genentech, Inc. Antibody variants
EP1950300A2 (en) 1998-11-18 2008-07-30 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6632926B1 (en) 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants
US7842789B2 (en) 1999-01-21 2010-11-30 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7507405B2 (en) 1999-01-21 2009-03-24 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US8147830B2 (en) 1999-01-21 2012-04-03 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US7214776B2 (en) 1999-01-21 2007-05-08 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US8652468B2 (en) 1999-01-21 2014-02-18 Genentech, Inc. Methods of binding TNF-α using anti-TNF-α antibody fragment-polymer conjugates
EP1854480A3 (en) * 1999-03-19 2009-04-01 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
JP2002540078A (ja) * 1999-03-19 2002-11-26 ジェネンテック・インコーポレーテッド Ｌｆａ−１アンタゴニスト投与量の増加によるｌｆａ−１関連疾患の治療
WO2000056363A1 (en) * 1999-03-19 2000-09-28 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
US6652855B1 (en) 1999-03-19 2003-11-25 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US7364734B2 (en) 1999-03-19 2008-04-29 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
AU768324B2 (en) * 1999-12-14 2003-12-11 Genentech Inc. TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
WO2001043773A1 (en) * 1999-12-14 2001-06-21 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US7964394B2 (en) 1999-12-30 2011-06-21 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
WO2001051084A1 (en) * 2000-01-14 2001-07-19 Genentech, Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US8241627B2 (en) * 2000-09-01 2012-08-14 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US20110305691A1 (en) * 2000-09-01 2011-12-15 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US7060492B2 (en) 2000-10-30 2006-06-13 Vbi Technologies, L.L.C. Isolation of spore-like cells from tissues exposed to extreme conditions
EP2048154A1 (en) 2002-02-05 2009-04-15 Genentech, Inc. Protein purification
US7323553B2 (en) 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US8858950B2 (en) 2002-11-27 2014-10-14 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP3095793B1 (en) 2003-07-28 2020-03-25 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US7807799B2 (en) 2003-07-28 2010-10-05 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
EP3722309A1 (en) 2003-07-28 2020-10-14 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US7485704B2 (en) 2003-07-28 2009-02-03 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
EP3095793A1 (en) 2003-07-28 2016-11-23 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
WO2005016968A2 (en) 2003-07-28 2005-02-24 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
US7927591B2 (en) * 2004-02-19 2011-04-19 The Cbr Institute For Biomedical Research, Inc. Conformation specific antibodies
AU2005215024B2 (en) * 2004-02-19 2011-07-21 Dyax Corp. Conformation specific antibodies
US8247185B2 (en) 2004-02-19 2012-08-21 Dyax Corp. Conformation specific antibodies
WO2005123777A3 (en) * 2004-06-09 2006-03-02 Genentech Inc Method of treating granuloma annulare or sarcoid
US7396530B2 (en) 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
EP3498294A1 (en) 2004-10-20 2019-06-19 Genentech, Inc. Antibody formulations
EP2371388A2 (en) 2004-10-20 2011-10-05 Genentech, Inc. Antibody formulations
US9090930B2 (en) 2006-06-27 2015-07-28 Emd Millipore Corporation Method and unit for preparing a sample for the microbiological analysis of a liquid
US9410181B2 (en) 2006-06-27 2016-08-09 Emd Millipore Corporation Method and unit for preparing a sample for the microbiological analysis of a liquid
US9376464B2 (en) 2006-12-21 2016-06-28 Emd Millipore Corporation Purification of proteins
US10233211B2 (en) 2006-12-21 2019-03-19 Emd Millipore Corporation Purification of proteins
US10793593B2 (en) 2006-12-21 2020-10-06 Emd Millipore Corporation Purification of proteins
EP2377527A1 (en) 2007-01-22 2011-10-19 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
EP4245766A2 (en) 2007-07-09 2023-09-20 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP4335863A2 (en) 2007-07-09 2024-03-13 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP4219522A2 (en) 2007-07-09 2023-08-02 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2586788A1 (en) 2007-07-09 2013-05-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP3327026A1 (en) 2007-07-09 2018-05-30 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP3597659A1 (en) 2007-07-09 2020-01-22 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP4365189A2 (en) 2007-07-09 2024-05-08 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2565206A2 (en) 2007-10-30 2013-03-06 Genentech, Inc. Antibody purification by cation exchange chromatography
EP2840090A1 (en) 2007-10-30 2015-02-25 Genentech, Inc. Antibody purification by cation exchange chromatography
EP3441402A1 (en) 2007-10-30 2019-02-13 Genentech, Inc. Antibody purification by cation exchange chromatography
WO2009058812A1 (en) 2007-10-30 2009-05-07 Genentech, Inc. Antibody purification by cation exchange chromatography
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
US10927144B2 (en) 2008-08-14 2021-02-23 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2848625A1 (en) 2008-08-14 2015-03-18 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US9803165B2 (en) 2008-12-16 2017-10-31 Emd Millipore Corporation Stirred tank reactor and method
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
WO2010099273A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
US10982003B2 (en) 2009-08-11 2021-04-20 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US12103975B2 (en) 2009-08-11 2024-10-01 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9714293B2 (en) 2009-08-11 2017-07-25 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
EP3760712A1 (en) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US12351641B2 (en) 2009-08-11 2025-07-08 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
WO2011028753A1 (en) 2009-09-01 2011-03-10 Genentech, Inc. Enhanced protein purification through a modified protein a elution
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
US9145545B2 (en) 2009-11-12 2015-09-29 Vbi Technologies, Llc Subpopulations of spore-like cells and uses thereof
US9663765B2 (en) 2009-11-12 2017-05-30 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
US11028363B2 (en) 2009-11-12 2021-06-08 Vcell Therapeutics, Inc. Subpopulations of spore-like cells and uses thereof
US8551775B2 (en) 2009-11-12 2013-10-08 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
US9999638B2 (en) 2009-11-12 2018-06-19 Vbi Technologies, L.L.C. Subpopulations of spore-like cells and uses thereof
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
US9662395B2 (en) 2010-03-22 2017-05-30 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP3513810A1 (en) 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions and methods useful for stabilizing protein- containing formulations
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
US9217048B2 (en) 2010-05-17 2015-12-22 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US8691918B2 (en) 2010-05-17 2014-04-08 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US9731288B2 (en) 2010-05-17 2017-08-15 Emd Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US10704071B2 (en) 2010-05-28 2020-07-07 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US10011856B2 (en) 2010-05-28 2018-07-03 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US9487809B2 (en) 2010-05-28 2016-11-08 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
US11046987B2 (en) 2010-05-28 2021-06-29 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
EP4008313A1 (en) 2010-06-24 2022-06-08 F. Hoffmann-La Roche AG Compositions and methods for stablizing protein-containing formulations
WO2011163458A2 (en) 2010-06-24 2011-12-29 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
EP3586826A1 (en) 2010-06-24 2020-01-01 F. Hoffmann-La Roche AG Compositions and methods for stabilizing protein-containing formulations
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US20130309244A1 (en) * 2010-12-21 2013-11-21 Duke University Methods and compositions combining immunotherapy with monocyte activation
US9814740B2 (en) 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
EP3492486A1 (en) 2011-12-22 2019-06-05 F. Hoffmann-La Roche AG Ion exchange membrane chromatography
WO2013096322A1 (en) 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
US11945837B2 (en) 2011-12-22 2024-04-02 Genentech, Inc. Ion exchange membrane chromatography
WO2013148249A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Improved harvest operations for recombinant proteins
WO2013173687A1 (en) 2012-05-18 2013-11-21 Genentech, Inc. High-concentration monoclonal antibody formulations
EP3427721A1 (en) 2012-05-18 2019-01-16 Genentech, Inc. High-concentration monoclonal antibody formulations
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
US10590190B2 (en) 2013-07-09 2020-03-17 Annexon, Inc. Anti-complement factor C1q antibodies and uses thereof
US10227398B2 (en) 2013-07-09 2019-03-12 Annexon, Inc. Anti-complement factor C1q antibodies and uses thereof
US11649279B2 (en) 2013-07-09 2023-05-16 Annexon, Inc. Anti-complement factor C1Q antibodies and uses thereof
WO2015006504A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
US10927167B2 (en) 2013-07-09 2021-02-23 Annexon, Inc. Anti-complement factor C1Q antibodies and uses thereof
EA037325B1 (ru) * 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
US9708394B2 (en) 2013-07-09 2017-07-18 Annexon, Inc. Anti-complement factor C1q antibodies and uses thereof
WO2016007752A1 (en) 2014-07-09 2016-01-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
US12016328B2 (en) 2014-07-09 2024-06-25 Genentech, Inc. PH adjustment to improve thaw recovery of cell banks
US10602739B2 (en) 2014-07-09 2020-03-31 Genentech, Inc. PH adjustment to improve thaw recovery of cell banks
EP3777535A1 (en) 2014-07-09 2021-02-17 F. Hoffmann-La Roche AG Ph adjustment to improve thaw recovery of cell banks
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
US10723788B2 (en) 2015-11-24 2020-07-28 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
US11999779B2 (en) 2015-11-24 2024-06-04 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
WO2017172994A1 (en) 2016-03-29 2017-10-05 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
WO2018119312A1 (en) 2016-12-22 2018-06-28 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11377505B2 (en) 2016-12-22 2022-07-05 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11214609B2 (en) 2017-09-28 2022-01-04 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11028148B2 (en) 2017-09-28 2021-06-08 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11041015B2 (en) 2017-09-28 2021-06-22 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
EP4368699A2 (en) 2018-07-03 2024-05-15 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2020010080A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
US11168126B2 (en) 2019-04-12 2021-11-09 Geltor, Inc. Recombinant elastin and production thereof
US12269865B2 (en) 2019-04-12 2025-04-08 Geltor, Inc. Recombinant elastin and production thereof
WO2021021973A1 (en) 2019-08-01 2021-02-04 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Also Published As

Publication number Publication date
DE122004000047I1 (de) 2005-04-21
KR100532178B1 (ko) 2005-12-01
EP0941344B1 (en) 2004-05-19
ATE267257T1 (de) 2004-06-15
EP1516629B1 (en) 2013-04-03
AU731817C (en) 2001-11-01
FR04C0028I1 (enrdf_load_stackoverflow) 2005-02-11
JP2001505425A (ja) 2001-04-24
CA2272842C (en) 2012-05-15
DE69729209T2 (de) 2005-05-19
DE122004000047I2 (de) 2006-06-14
NL300163I1 (nl) 2005-01-03
KR20000069147A (ko) 2000-11-25
EP1516629A2 (en) 2005-03-23
LU91122I2 (fr) 2005-01-10
EP0941344A1 (en) 1999-09-15
AU731817B2 (en) 2001-04-05
EP1516629A3 (en) 2006-09-27
AU4992997A (en) 1998-06-22
ES2221045T3 (es) 2004-12-16
PT941344E (pt) 2004-10-29
DK1516629T3 (da) 2013-06-03
AR008919A1 (es) 2000-02-23
NL300163I2 (nl) 2005-07-01
FR04C0028I2 (enrdf_load_stackoverflow) 2007-10-26
ZA979599B (en) 1999-04-28
CA2272842A1 (en) 1998-06-04
DK0941344T3 (da) 2004-09-27
JP4309383B2 (ja) 2009-08-05
IL175583A0 (en) 2006-09-05
IL130143A (en) 2006-08-01
JP2006036779A (ja) 2006-02-09
IL130143A0 (en) 2000-06-01
JP3778945B2 (ja) 2006-05-24
DE69729209D1 (de) 2004-06-24

Similar Documents

Publication Publication Date Title
AU731817C (en) Humanized anti-CD11a antibodies
US6703018B2 (en) Method of treatment using humanized anti-CD11a antibodies
EP1948798B1 (en) Anti-alpha2 integrin antibodies and their uses
JP6289375B2 (ja) 抗ｉｌ−３６ｒ抗体
US20080241126A1 (en) Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAM
KR20010014422A (ko) 개선된 항-ＩｇＥ 항체 및 폴리펩티드의 개선 방법
JP2015145397A (ja) 抗α２インテグリン抗体を使用する処置
KR20120130773A (ko) 항-알파2 인테그린 항체 및 그 용도
JP2024505674A (ja) 抗ｉｌ１ｒａｐ抗体
US20040146507A1 (en) Antibody mutants
EP0946727B1 (en) Antibody mutants
MXPA99004795A (en) HUMANIZED ANTI-CD11a ANTIBODIES
HK1121186B (en) Anti-alpha2 integrin antibodies and their uses
MX2008006459A (en) Anti-alpha2 integrin antibodies and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004795

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1998 524645

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2272842

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019997004671

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997912841

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997912841

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997004671

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997912841

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997004671

Country of ref document: KR